1268486-66-3Relevant academic research and scientific papers
Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity
Nordqvist, Anneli,O'Mahony, Gavin,Fridén-Saxin, Maria,Fredenwall, Marlene,Hogner, Anders,Granberg, Kenneth L.,Aagaard, Anna,B?ckstr?m, Stefan,Gunnarsson, Anders,Kaminski, Tim,Xue, Yafeng,Dellsén, Anita,Hansson, Eva,Hansson, Pia,Ivarsson, Ida,Karlsson, Ulla,Bamberg, Krister,Hermansson, Majlis,Georgsson, Jennie,Lindmark, Bo,Edman, Karl
, p. 50 - 65 (2017)
The mineralocorticoid receptor (MR) is a nuclear hormone receptor involved in the regulation of body fluid and electrolyte homeostasis. In this study we explore selectivity triggers for a series of nonsteroidal MR antagonists to improve selectivity over other members of the oxosteroid receptor family. A biaryl sulfonamide compound was identified in a high-throughput screening (HTS) campaign. The compound bound to MR with pKi=6.6, but displayed poor selectivity over the glucocorticoid receptor (GR) and the progesterone receptor (PR). Following X-ray crystallography of MR in complex with the HTS hit, a compound library was designed that explored an induced-fit hypothesis that required movement of the Met852 side chain. An improvement in MR selectivity of 11- to 79-fold over PR and 23- to 234-fold over GR was obtained. Given the U-shaped binding conformation, macrocyclizations were explored, yielding a macrocycle that bound to MR with pKi=7.3. Two protein–ligand X-ray structures were determined, confirming the hypothesized binding mode for the designed compounds.
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist
Brown, Angus R.,Bosies, Michael,Cameron, Helen,Clark, John,Cowley, Angela,Craighead, Mark,Elmore, Moira A.,Firth, Alistair,Goodwin, Richard,Goutcher, Susan,Grant, Emma,Grassie, Morag,Grove, Simon J.A.,Hamilton, Niall M.,Hampson, Hannah,Hillier, Alison,Ho, Koc-Kan,Kiczun, Michael,Kingsbury, Celia,Kultgen, Steven G.,Littlewood, Peter T.A.,Lusher, Scott J.,MacDonald, Susan,McIntosh, Lorraine,McIntyre, Theresa,Mistry, Ashvin,Morphy, J. Richard,Nimz, Olaf,Ohlmeyer, Michael,Pick, Jack,Rankovic, Zoran,Sherborne, Brad,Smith, Alasdair,Speake, Michael,Spinks, Gayle,Thomson, Fiona,Watson, Lynn,Weston, Mark
scheme or table, p. 137 - 140 (2011/02/27)
High-throughput screening of 3.87 million compounds delivered a novel series of non-steroidal GR antagonists. Subsequent rounds of optimisation allowed progression from a non-selective ligand with a poor ADMET profile to an orally bioavailable, selective, stable, glucocorticoid receptor antagonist.
